Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. Issue 9 (1st August 2019)

• Record Type: Journal Article
• Authors: Bos, Isabelle; Vos, Stephanie J.B.; Schindler, Suzanne E.; Hassenstab, Jason; Xiong, Chengjie; Grant, Elizabeth; Verhey, Frans; Morris, John C.; Visser, Pieter Jelle; Fagan, Anne M.
• Is Part Of: Alzheimer's & dementia. Volume 15:Issue 9(2019)
• Page Start: 1149
• Page End: 1159
• Publication Date: 2019-08-01
• Subjects: Alzheimer's disease -- Dementia -- Cerebrospinal fluid -- Biomarkers -- Amyloid‐β -- Tau -- Neurodegeneration -- Vascular risk factors -- Hypertension -- Obesity -- Hypercholesterolemia -- Depression -- Cardiovascular disorders -- Framingham Risk Score; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2019.04.015
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Vascular factors increase the risk of Alzheimer's disease (AD). We investigated the associations between such factors, longitudinal AD cerebrospinal fluid biomarkers, and cognition. Methods: 433 cognitively normal participants were classified into four biomarker groups using their baseline amyloid (A+/−) and tau status (T+/−). 184 participants had undergone serial cerebrospinal fluid collection. Frequencies of risk factors and the Framingham Risk Score (FRS) were compared, and we tested the influence of risk factors on change in biomarker concentrations and cognition. Results: The absence of obesity, presence of hypertension, and a high FRS were associated with an increase in tau levels, particularly in A+T+ individuals. Risk factors were not associated with amyloid. Depression was associated with higher cognitive scores, whereas high FRS was associated with lower scores and a faster decline. Discussion: Our results demonstrate that vascular risk factors may enhance neurodegeneration but not amyloid accumulation in preclinical AD.